

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Daniel Nava Rodrigues, ... , Eliezer M. Van Allen, Johann S. de Bono

J Clin Invest. 2018;128(11):5185-5185. <https://doi.org/10.1172/JCI125184>.

Corrigendum

Original citation: *J Clin Invest.* 2018;128(10):4441–4453. <https://doi.org/10.1172/JCI121924>

Citation for this corrigendum: *J Clin Invest.* 2018;128(11):5185.

<https://doi.org/10.1172/JCI125184> Charles L. Sawyers's conflict-of-interest statement was not included in the manuscript. The correct statement is below. CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014. The authors regret the error.

Find the latest version:

<http://jci.me/125184/pdf>



Corrigendum

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B. Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P. Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T. Schweizer, Colin C. Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A. Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D'Andrea, Charles L. Sawyers, Arul M. Chinnaiyan, Andrea Alimonti, Peter S. Nelson, Charles G. Drake, Eliezer M. Van Allen, and Johann S. de Bono

Original citation: *J Clin Invest*. 2018;128(10):4441-4453. <https://doi.org/10.1172/JCI121924>.

Citation for this corrigendum: *J Clin Invest*. 2018;128(11):5185. <https://doi.org/10.1172/JCI125184>.

Charles L. Sawyers's conflict-of-interest statement was not included in the manuscript. The correct statement is below.

CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014.

The authors regret the error.

Erratum

Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy

Lara Al-Olabi, Satyamaanasa Polubothu, Katherine Dowsett, Katrina A. Andrews, Paulina Stadnik, Agnel P. Joseph, Rachel Knox, Alan Pittman, Graeme Clark, William Baird, Neil Bulstrode, Mary Glover, Kristiana Gordon, Darren Hargrave, Susan M. Huson, Thomas S. Jacques, Gregory James, Hannah Kondolf, Loshan Kangesu, Kim M. Keppler-Noreuil, Amjad Khan, Marjorie J. Lindhurst, Mark Lipson, Sahar Mansour, Justine O'Hara, Caroline Mahon, Anda Mosica, Celia Moss, Aditi Murthy, Juling Ong, Victoria E. Parker, Jean-Baptiste Rivière, Julie C. Sapp, Neil J. Sebire, Rahul Shah, Branavan Sivakumar, Anna Thomas, Alex Virasami, Regula Waelchli, Zhiqiang Zeng, Leslie G. Biesecker, Alex Barnacle, Maya Topf, Robert K. Semple, E. Elizabeth Patton, and Veronica A. Kinsler

Original citation: *J Clin Invest*. 2018;128(4):1496-1508. <https://doi.org/10.1172/JCI98589>.

Citation for this corrigendum: *J Clin Invest*. 2018;128(11):5185. <https://doi.org/10.1172/JCI124649>.

In Table 2, the mutation for patient no. 11 in the column labeled "cDNA, aa change" is incorrect. The correct mutation is NM_002524.4:c.182A>G; NRAS p.(Q61R).

The *JCI* regrets the error.